Puma Biotechnology (PBYI) Insider Stuglik Sells $58K of Stock

Puma Biotechnology Insider Brian Stuglik Sells Stock

Puma Biotechnology, Inc. (NasdaqGS: PBYI) saw internal share sales on June 12, 2026, when insider Brian Stuglik disposed of 8,100 shares. The transaction was executed at a price of $7.20 per share, resulting in a total value of $58,320. The sale was carried out as part of a pre-arranged trading plan.

Broad Insider Sales at Puma Biotechnology

The transaction by Stuglik was part of a larger group of scheduled sales that took place on June 12, 2026. Wilson Troy Edward sold 10,800 shares at a price of $7.20 for a total value of $77,760. Jay Moyes offloaded 22,000 shares at an average price of $7.22, totaling $158,840. Adrian Senderowicz also parted with 27,000 shares at a price of $7.20, bringing that transaction to $194,400. All of these insider dispositions were structured under planned trading arrangements.

Puma Biotechnology Stock Valuation

PBYI shares traded near the spot price of $7.33 around the time of recent market updates. The biopharmaceutical firm holds a trailing price-to-earnings ratio of 18.8 and a forward price-to-earnings ratio of 27.4. The equity has moved between a 52-week low of $4.47 and a 52-week high of $9.75, keeping it positioned within its established yearly range.

Recent Earnings for the Cancer-Drug Developer

The healthcare company generates revenue through its commercialized therapies focused on enhancing cancer care. Annual revenue reached $231.2 million, accompanied by a revenue growth rate of 7.8%. The firm reported a net margin of 11.6% and an annual return on equity of 22.0%. Financial participants look toward the upcoming results slated for November 5, 2026.

Analysts Set New Price Targets

Financial firms monitor the healthcare company's market progress through ongoing research coverage. On August 7, 2026, TD Cowen maintained its hold rating on the stock while adjusting its price target from $5.00 to $6.00.

Inside the Operations of Puma Biotechnology

Puma Biotechnology focuses on developing and commercializing therapeutic products designed to improve treatment outcomes for cancer patients. Its principal offerings include treatments targeting specific forms of breast cancer through specialized distribution networks. The company also maintains licensing agreements with various pharmaceutical partners to advance ongoing clinical research.

Looking Ahead for PBYI

Market observers will continue tracking future regulatory updates, partnership developments, and upcoming financial disclosures from the company. Insider transactions filed with regulatory bodies offer a transparent view of internal management adjustments without signaling broader directional changes in the business.